Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-01

Clinical Trial Update: Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on adding pegylated interferon alfa-2a to chronic hepatitis B patients already treated with nucleos(t)ide analogs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: The Second Affiliated Hospital of Chongqing Medical University | Conditions: Hepatitis B | Phase 4 | Status: UNKNOWN